First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

Italiano A.Cassier P.A.CHIA-CHI LINAlanko T.Peltola K.J.Gazzah A.Shiah H.-S.Calvo E.Cervantes A.Roda D.Tosi D.Gao B.Millward M.Warburton L.Tanner M.Englert S.Lambert S.Parikh A.Afar D.E.Vosganian G.Moreno V.2022-09-152022-09-1520220340-7004https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109344549&doi=10.1007%2fs00262-021-02973-w&partnerID=40&md5=1460756dafddfaa1e2f33275c4f3423bhttps://scholars.lib.ntu.edu.tw/handle/123456789/620206[SDGs]SDG3First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinomajournal article10.1007/s00262-021-02973-w342162472-s2.0-85109344549